|
August 12, 2010 |
Spectral Announces Second Quarter 2010 Results
|
|
June 23, 2010 |
Spectral Receives McMaster Industry Partner of the Year
Award for Aptamer Discovery Research |
|
May
14, 2010 |
Spectral Announces First Quarter Financial Results
|
|
March 12, 2010
|
Spectral Announces Presentations at the 8th Annual World
Congress on Trauma, Shock, Inflammation and Sepsis Focusing
on the Role of Endotoxin
|
|
March 11, 2010
|
Spectral
Announces 2009 Results
|
March
10, 2010
|
Spectral Appoints Two New Board Members |
|
March
3, 2010 |
Spectral
Closes $19.5 Million Private Placement Financing |
|
March 2, 2010 |
Spectral Granted IDE Approval by U.S. FDA to Conduct Pivotal
Trial for Toraymyxin™ |
|
February
26, 2010 |
Spectral Shareholders Approve $19.5 Million Private
Placement Financing |
|
February 3, 2010 |
Spectral
Increases Private Placement Financing to $19.5 Million |
|
December 17,
2009 |
Spectral
Diagnostics Raises $14 Million and Enters into Strategic
Collaboration with BIOMS Medical to Commercialize Treatment
for Sepsis
Spectral & BioMS Audiocast View a slide
presentation and audio recording by Dr.
Paul
Walker,
President and CEO
of Spectral and Mr. Kevin
Giese, President and CEO of BioMS Medical where they discuss
this collaboration and the opportunity for Toraymyxin™ in
the treatment of severe sepsis.
|
|
November 12,
2009 |
Spectral
Announces Third Quarter 2009 Results
|
|
August
13, 2009 |
Spectral
Appoints New Board Member |
|
August 13, 2009 |
Spectral
Announces Second Quarter 2009 Results |
|
June 18, 2009 |
Spectral
Announces Publication Demonstrating Toraymyxin™
Significantly Reduces Mortality from Sepsis in Prospective
Controlled Trial |
|
May 14, 2009 |
Spectral
Announces First Quarter 2009 Results |
|
March
25, 2009 |
Spectral
Announces Presentations at the 29th International Symposium
on Intensive Care and Emergency Medicine
Focusing on the Role of Endotoxin |
|
March
12, 2009 |
Spectral
Announces 2008 Financial Results |
|
March 9,
2009 |
Spectral
Signs Exclusive License Agreement to Bring Sepsis
Therapeutic to the U.S. Market |
|
February 23, 2009 |
Spectral
Presents Data on the Clinical Utility of EAA™ at 13th Annual
Critical Care for Endotoxemia Conference in Japan |
|
November 12, 2008 |
Spectral
Announces Third Quarter 2008 Results |
|
September 23, 2008 |
Spectral
to Bring
Anti-Sepsis Therapy to the U.S. Market |
|
August 13, 2008 |
Spectral Announces
Second Quarter 2008 Results |
|
July
10, 2008 |
Spectral Announces
Exclusive
Distribution Agreement in Russia for its EAA™ Sepsis
Diagnostic Assay |
|
June
26, 2008 |
Spectral Announces
Continuing
Support for the Combination of EAA™ and
Anti-Endotoxin Therapeutics
|
|
June 2, 2008 |
Spectral Announces
Presentation of
Data on Improving Sepsis Patient Management with EAA™ and
Toraymyxin™ Combination |
|
May
14, 2008 |
Spectral
Announces First Quarter 2008 Results |
|
May 5, 2008 |
Spectral
and Toray Expand Collaboration to Include New Geographic
Territories |
|
April 9, 2008 |
Spectral's
EAA™ to be Used in Phase III Study for a Sepsis Anti-Endotoxin
Therapy |
|
March 18, 2008 |
Spectral Announces New Findings on the Effectiveness of EAA™/Toraymyxin™
at the 28th International Symposium on Intensive Care and
Emergency Medicine |
